Zegalogue Autoinjector (dasiglucagon HCl)
Last reviewed · Source: First Databank (FDB) drug data
Overview
Dasiglucagon, an antihypoglycemic agent, is a glucagon analog that increases blood glucose concentration by stimulating hepatic glycogenolysis.
Dasiglucagon, an antihypoglycemic agent, is a peptide analog of human glucagon, a hormone synthesized and secreted by the alpha2 cells of the pancreatic islets of Langerhans. Dasiglucagon consists of 29 amino acids with 7 amino acid substitutions relative to glucagon that increase stability of the drug in aqueous solution at physiologic pH. Dasiglucagon, a glucagon receptor agonist, increases blood glucose concentration by activating hepatic glucagon receptors, thereby stimulating hepatic glycogenolysis and release of glucose from the liver.
Dasiglucagon and glucagon have similar potency at the human glucagon receptor. The availability of dasiglucagon injection and more stable parenteral and intranasal formulations of glucagon provide opportunities to expand the use of this hormone in managing insulin-induced hypoglycemia in nonhospital settings. (See Glucagon 68:22.12.)
Following sub-Q administration of a single 0.6-mg dose dasiglucagon in adults with type 1 diabetes mellitus, the mean peak plasma concentration of the drug was attained in approximately 35 minutes and the mean increase in glucose concentration from baseline to 90 minutes was 168 mg/dL. In pediatric patients with type 1 diabetes mellitus, the mean peak plasma concentration of the drug was attained in approximately 21 minutes and the mean increase in glucose concentration from baseline to 60 minutes was 162 mg/dL. Like endogenous glucagon, dasiglucagon is eliminated via proteolytic degradation in the blood, liver, and kidneys.
The half-life of dasiglucagon is approximately 30 minutes.
USES: This medication is like your body's own glucagon, a natural substance that raises blood sugar by causing the body to release sugar stored in the liver. It is used to treat very low blood sugar (hypoglycemia) that may cause you to need help from others. Before you need help, make sure a family member or caregiver knows where you keep this medication and how to use it.
Generic name: dasiglucagon HCl
Pronunciation: (DAS-i-GLOO-ka-gon)
Reference product & biosimilars
No reference, biosimilar or interchangeable associated with this drug.
Today’s intelligence on Zegalogue Autoinjector
Indications
The following indications are listed for Zegalogue Autoinjector:
- Hypoglycemic Disorder
Also known as: Hypoglycemia.
Dosing
Dosage of dasiglucagon hydrochloride is expressed in terms of dasiglucagon.
Dasiglucagon is administered by sub-Q injection only. Injection sites include the lower abdomen, buttocks, thigh, and outer upper arm.
Dasiglucagon is supplied in single-use auto-injectors and prefilled syringes. Dasiglucagon injection should be inspected visually prior to administration. The solution should appear clear, colorless, and free from particles and should be discarded if it is discolored or contains particulate matter.
Dasiglucagon should be administered as soon as possible after severe hypoglycemia is recognized. Immediately following administration, emergency assistance should be summoned. If the patient has not responded within 15 minutes after the initial dose, an additional dose may be administered using a new auto-injector or prefilled syringe while awaiting emergency assistance. Once the patient has responded to treatment, oral carbohydrates should be administered to restore liver glycogen stores and to prevent recurrence of hypoglycemia.
No dosing information is available for this tab.
No dosing information is available for this tab.
Drug interactions
There is no enhanced messaging for this drug.
There are no contraindication interactions for this drug.
There are no severe interactions for this drug.
There are no moderate interactions for this drug.
Contraindications
Dasiglucagon is contraindicated in patients with pheochromocytoma because of the risk of substantial increase in blood pressure and in those with insulinoma because of the risk of hypoglycemia.
There are no contraindication contraindications for this drug.
There are no severe contraindications for this drug.
There are no moderate contraindications for this drug.
Adverse reactions
Adverse effects reported in 2% or more of adults or pediatric patients receiving dasiglucagon include nausea, vomiting, headache, and injection site pain. Diarrhea also has been reported in 2% or more of adults receiving the drug.
There are no severe adverse reactions for this drug.
There are no less severe adverse reactions for this drug.
Precautions
No enhanced messaging available.
Safety and efficacy of dasiglucagon for the treatment of severe hypoglycemia in pediatric patients 6 years of age and older with diabetes mellitus are supported by evidence from a controlled study in 42 pediatric patients with type 1 diabetes mellitus. (See Hypoglycemia under Uses.) Safety and efficacy of the drug have not been established in pediatric patients younger than 6 years of age.
There are no available data regarding use of dasiglucagon in pregnant women by which to establish a drug-associated risk of major birth defects, spontaneous abortion, or adverse maternal or fetal outcomes. Untreated hypoglycemia during pregnancy can cause complications and can be fatal.
In animal reproduction studies, daily sub-Q administration of dasiglucagon to pregnant rabbits and rats during the period of organogenesis did not cause adverse developmental effects at exposure levels of 7 and 709 times, respectively, the recommended human dose of 0.6 mg; in rabbits at dosages of 20 or more times the recommended human dose, dasiglucagon caused fetal skeletal and visceral malformations.
It is not known whether dasiglucagon is distributed into human or animal milk, affects breast-fed infants, or affects milk production. Because dasiglucagon is a peptide and would be expected to be broken down to its constituent amino acids in an infant's digestive tract, the drug is unlikely to harm breast-fed infants.
Clinical studies of dasiglucagon did not include sufficient numbers of patients 65 years of age and older to determine whether geriatric patients respond differently than younger adults.
ICD codes
No ICD codes are available for this drug.
Formulary status
Search health-plan coverage for this drug by ZIP code.
Choose the first character of a health plan name.
Last reviewed · Source: First Databank (FDB) drug data
On this page
Actions
Sign in to save favorites
Saving this drug requires a free Physicians Office Resource account.